Conformational diversity and protein-protein interfaces in drug repurposing in Ras signaling pathway.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 Jan 2024
12 Jan 2024
Historique:
received:
14
08
2023
accepted:
27
12
2023
medline:
13
1
2024
pubmed:
13
1
2024
entrez:
12
1
2024
Statut:
epublish
Résumé
We focus on drug repurposing in the Ras signaling pathway, considering structural similarities of protein-protein interfaces. The interfaces formed by physically interacting proteins are found from PDB if available and via PRISM (PRotein Interaction by Structural Matching) otherwise. The structural coverage of these interactions has been increased from 21 to 92% using PRISM. Multiple conformations of each protein are used to include protein dynamics and diversity. Next, we find FDA-approved drugs bound to structurally similar protein-protein interfaces. The results suggest that HIV protease inhibitors tipranavir, indinavir, and saquinavir may bind to EGFR and ERBB3/HER3 interface. Tipranavir and indinavir may also bind to EGFR and ERBB2/HER2 interface. Additionally, a drug used in Alzheimer's disease can bind to RAF1 and BRAF interface. Hence, we propose a methodology to find drugs to be potentially used for cancer using a dataset of structurally similar protein-protein interface clusters rather than pockets in a systematic way.
Identifiants
pubmed: 38216592
doi: 10.1038/s41598-023-50913-8
pii: 10.1038/s41598-023-50913-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1239Subventions
Organisme : TUSEB
ID : 4418
Informations de copyright
© 2024. The Author(s).
Références
Hughes, J., Rees, S., Kalindjian, S. & Philpott, K. Principles of early drug discovery. Br. J. Pharmacol. 162, 1239–1249. https://doi.org/10.1111/j.1476-5381.2010.01127.x (2011).
doi: 10.1111/j.1476-5381.2010.01127.x
pubmed: 21091654
pmcid: 3058157
Schlander, M., Hernandez-Villafuerte, K., Cheng, C.-Y., Mestre-Ferrandiz, J. & Baumann, M. How much does it cost to research and develop a new drug? A systematic review and assessment. PharmacoEconomics 39, 1243–1269. https://doi.org/10.1007/s40273-021-01065-y (2021).
doi: 10.1007/s40273-021-01065-y
pubmed: 34368939
pmcid: 8516790
Ashburn, T. T. & Thor, K. B. Drug repositioning: Identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673–683. https://doi.org/10.1038/nrd1468 (2004).
doi: 10.1038/nrd1468
pubmed: 15286734
Pushpakom, S. Drug Repurposing 1–13 (The Royal Society of Chemistry, 2022).
doi: 10.1039/9781839163401-00001
Adasme, M. F., Parisi, D., Sveshnikova, A. & Schroeder, M. Structure-based drug repositioning: Potential and limits. Semin. Cancer Biol. 68, 192–198. https://doi.org/10.1016/j.semcancer.2020.01.010 (2021).
doi: 10.1016/j.semcancer.2020.01.010
pubmed: 32032699
Singh, N., Chaput, L. & Villoutreix, B. O. Virtual screening web servers: Designing chemical probes and drug candidates in the cyberspace. Brief. Bioinform. 22, 1790–1818. https://doi.org/10.1093/bib/bbaa034 (2021).
doi: 10.1093/bib/bbaa034
pubmed: 32187356
Wang, F. et al. ACID: A free tool for drug repurposing using consensus inverse docking strategy. J. Cheminform. 11, 73. https://doi.org/10.1186/s13321-019-0394-z (2019).
doi: 10.1186/s13321-019-0394-z
pubmed: 33430982
pmcid: 6882193
Tsai, K.-L., Chang, S.-Y. & Yang, L.-W. DRDOCK: A drug repurposing platform integrating automated docking, simulations and a log-odds-based drug ranking scheme. bioRxiv https://doi.org/10.1101/2021.01.31.429052 (2021).
doi: 10.1101/2021.01.31.429052
pubmed: 34341789
pmcid: 8328056
Labbé, C. M. et al. MTiOpenScreen: A web server for structure-based virtual screening. Nucleic Acids Res. 43, W448–W454. https://doi.org/10.1093/nar/gkv306 (2015).
doi: 10.1093/nar/gkv306
pubmed: 25855812
pmcid: 4489289
Nair, A., Chauhan, P., Saha, B. & Kubatzky, K. F. Conceptual evolution of cell signaling. Int. J. Mol. Sci. 20, 3292. https://doi.org/10.3390/ijms20133292 (2019).
doi: 10.3390/ijms20133292
pubmed: 31277491
pmcid: 6651758
Guo, Y. J. et al. ERK/MAPK signalling pathway and tumorigenesis (Review). Exp. Ther. Med. 19, 1997–2007. https://doi.org/10.3892/etm.2020.8454 (2020).
doi: 10.3892/etm.2020.8454
pubmed: 32104259
pmcid: 7027163
Plotnikov, A., Zehorai, E., Procaccia, S. & Seger, R. The MAPK cascades: Signaling components, nuclear roles and mechanisms of nuclear translocation. Biochim. Biophys. Acta BBA Mol. Cell Res. 1813, 1619–1633. https://doi.org/10.1016/j.bbamcr.2010.12.012 (2011).
doi: 10.1016/j.bbamcr.2010.12.012
Shaul, Y. D. & Seger, R. The MEK/ERK cascade: From signaling specificity to diverse functions. Biochim. Biophys. Acta (BBA) Mol. Cell Res. 1773, 1213–1226. https://doi.org/10.1016/j.bbamcr.2006.10.005 (2007).
doi: 10.1016/j.bbamcr.2006.10.005
Raman, M., Chen, W. & Cobb, M. H. Differential regulation and properties of MAPKs. Oncogene 26, 3100–3112. https://doi.org/10.1038/sj.onc.1210392 (2007).
doi: 10.1038/sj.onc.1210392
pubmed: 17496909
Albert-Gasco, H., Ros-Bernal, F., Castillo-Gomez, E. & Olucha-Bordonau, F. E. MAP/ERK signaling in developing cognitive and emotional function and its effect on pathological and neurodegenerative processes. Int. J. Mol. Sci. https://doi.org/10.3390/ijms21124471 (2020).
doi: 10.3390/ijms21124471
pubmed: 32586047
pmcid: 7352860
Tartaglia, M. & Gelb, B. D. Disorders of dysregulated signal traffic through the RAS-MAPK pathway: Phenotypic spectrum and molecular mechanisms. Ann. N. Y. Acad. Sci. 1214, 99–121. https://doi.org/10.1111/j.1749-6632.2010.05790.x (2010).
doi: 10.1111/j.1749-6632.2010.05790.x
pubmed: 20958325
pmcid: 3010252
Lu, N. & Malemud, C. J. Extracellular signal-regulated kinase: A regulator of cell growth, inflammation, chondrocyte and bone cell receptor-mediated gene expression. Int. J. Mol. Sci. 20, 3792 (2019).
doi: 10.3390/ijms20153792
pubmed: 31382554
pmcid: 6696446
Dhillon, A. S., Hagan, S., Rath, O. & Kolch, W. MAP kinase signalling pathways in cancer. Oncogene 26, 3279–3290. https://doi.org/10.1038/sj.onc.1210421 (2007).
doi: 10.1038/sj.onc.1210421
pubmed: 17496922
Lee, S., Rauch, J. & Kolch, W. Targeting MAPK signaling in cancer: Mechanisms of drug resistance and sensitivity. Int. J. Mol. Sci. https://doi.org/10.3390/ijms21031102 (2020).
doi: 10.3390/ijms21031102
pubmed: 33396939
pmcid: 7795533
Schreiber, G. Protein–Protein Interaction Regulators 1–24 (The Royal Society of Chemistry, 2021).
Ryan, D. P. & Matthews, J. M. Protein–protein interactions in human disease. Curr. Opin. Struct. Biol. 15, 441–446. https://doi.org/10.1016/j.sbi.2005.06.001 (2005).
doi: 10.1016/j.sbi.2005.06.001
pubmed: 15993577
Wells, J. A. & McClendon, C. L. Reaching for high-hanging fruit in drug discovery at protein–protein interfaces. Nature 450, 1001–1009. https://doi.org/10.1038/nature06526 (2007).
doi: 10.1038/nature06526
pubmed: 18075579
Ivanov, A. A., Khuri, F. R. & Fu, H. Targeting protein–protein interactions as an anticancer strategy. Trends Pharmacol. Sci. 34, 393–400. https://doi.org/10.1016/j.tips.2013.04.007 (2013).
doi: 10.1016/j.tips.2013.04.007
pubmed: 23725674
pmcid: 3773978
Keskin, O., Haliloglu, T., Ma, B. & Nussinov, R. in Biophysical Journal 267A (Biophysical Society) (2004).
Tuncbag, N., Gursoy, A., Guney, E., Nussinov, R. & Keskin, O. Architectures and functional coverage of protein-protein interfaces. J. Mol. Biol. 381, 785–802. https://doi.org/10.1016/j.jmb.2008.04.071 (2008).
doi: 10.1016/j.jmb.2008.04.071
pubmed: 18620705
pmcid: 2605427
Cukuroglu, E., Gursoy, A., Nussinov, R. & Keskin, O. Non-redundant unique interface structures as templates for modeling protein interactions. PLoS One 9, e86738. https://doi.org/10.1371/journal.pone.0086738 (2014).
doi: 10.1371/journal.pone.0086738
pubmed: 24475173
pmcid: 3903793
Engin, H. B., Keskin, O., Nussinov, R. & Gursoy, A. A strategy based on protein-protein interface motifs may help in identifying drug off-targets. J. Chem. Inf. Model. 52, 2273–2286. https://doi.org/10.1021/ci300072q (2012).
doi: 10.1021/ci300072q
pubmed: 22817115
pmcid: 3979525
Fischer, P. M. Approved and experimental small-molecule oncology kinase inhibitor drugs: A mid-2016 overview. Med. Res. Rev. 37, 314–367. https://doi.org/10.1002/med.21409 (2017).
doi: 10.1002/med.21409
pubmed: 27775829
Li, H. et al. Protein degradation technology: A strategic paradigm shift in drug discovery. J. Hematol. Oncol. 14, 138. https://doi.org/10.1186/s13045-021-01146-7 (2021).
doi: 10.1186/s13045-021-01146-7
pubmed: 34488823
pmcid: 8419833
Lazo, J. S. & Sharlow, E. R. Drugging undruggable molecular cancer targets. Annu. Rev. Pharmacol. Toxicol. 56, 23–40. https://doi.org/10.1146/annurev-pharmtox-010715-103440 (2016).
doi: 10.1146/annurev-pharmtox-010715-103440
pubmed: 26527069
Weagel, E. G., Foulks, J. M., Siddiqui, A. & Warner, S. L. Molecular glues: Enhanced protein-protein interactions and cell proteome editing. Med. Chem. Res. 31, 1068–1087. https://doi.org/10.1007/s00044-022-02882-2 (2022).
doi: 10.1007/s00044-022-02882-2
Berman, H. M. et al. The protein data bank. Nucleic Acids Res. 28, 235–242. https://doi.org/10.1093/nar/28.1.235 (2000).
doi: 10.1093/nar/28.1.235
pubmed: 10592235
pmcid: 102472
Baspinar, A., Cukuroglu, E., Nussinov, R., Keskin, O. & Gursoy, A. PRISM: A web server and repository for prediction of protein–protein interactions and modeling their 3D complexes. Nucleic Acids Res. 42, W285–W289. https://doi.org/10.1093/nar/gku397 (2014).
doi: 10.1093/nar/gku397
pubmed: 24829450
pmcid: 4086120
Tuncbag, N., Gursoy, A., Nussinov, R. & Keskin, O. Predicting protein-protein interactions on a proteome scale by matching evolutionary and structural similarities at interfaces using PRISM. Nat. Protoc. 6, 1341–1354. https://doi.org/10.1038/nprot.2011.367 (2011).
doi: 10.1038/nprot.2011.367
pubmed: 21886100
pmcid: 7384353
Kuzu, G., Gursoy, A., Nussinov, R. & Keskin, O. Exploiting conformational ensembles in modeling protein-protein interactions on the proteome scale. J. Proteome Res. 12, 2641–2653. https://doi.org/10.1021/pr400006k (2013).
doi: 10.1021/pr400006k
pubmed: 23590674
pmcid: 3685852
Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947–1951. https://doi.org/10.1002/pro.3715 (2019).
doi: 10.1002/pro.3715
pubmed: 31441146
pmcid: 6798127
Kanehisa, M., Furumichi, M., Sato, Y., Ishiguro-Watanabe, M. & Tanabe, M. KEGG: Integrating viruses and cellular organisms. Nucleic Acids Res. 49, D545–D551. https://doi.org/10.1093/nar/gkaa970 (2020).
doi: 10.1093/nar/gkaa970
pmcid: 7779016
Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30. https://doi.org/10.1093/nar/28.1.27 (2000).
doi: 10.1093/nar/28.1.27
pubmed: 10592173
pmcid: 102409
Szklarczyk, D. et al. STRING v11: Protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47, D607–D613. https://doi.org/10.1093/nar/gky1131 (2018).
doi: 10.1093/nar/gky1131
pmcid: 6323986
Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583–589. https://doi.org/10.1038/s41586-021-03819-2 (2021).
doi: 10.1038/s41586-021-03819-2
pubmed: 34265844
pmcid: 8371605
Varadi, M. et al. AlphaFold protein structure database: Massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. 50, D439–D444. https://doi.org/10.1093/nar/gkab1061 (2021).
doi: 10.1093/nar/gkab1061
pmcid: 8728224
Perrone, G., Unpingco, J. & Lu, H.-M. Network visualizations with Pyvis and VisJS (2020).
Abali, Z. A data-centric approach for investigation of protein-protein interfaces in Protein Data Bank Data Science thesis (Koc University, 2021).
Nguyen, N. T. et al. Autodock Vina adopts more accurate binding poses but Autodock4 forms better binding affinity. J. Chem. Inf. Model. 60, 204–211. https://doi.org/10.1021/acs.jcim.9b00778 (2020).
doi: 10.1021/acs.jcim.9b00778
pubmed: 31887035
Shatsky, M., Nussinov, R. & Wolfson, H. J. A method for simultaneous alignment of multiple protein structures. Proteins Struct. Funct. Bioinform. 56, 143–156. https://doi.org/10.1002/prot.10628 (2004).
doi: 10.1002/prot.10628
Laskowski, R. A. & Swindells, M. B. LigPlot+: Multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model. 51, 2778–2786. https://doi.org/10.1021/ci200227u (2011).
doi: 10.1021/ci200227u
pubmed: 21919503
Knudsen, M. & Wiuf, C. The CATH database. Hum. Genomics 4, 207–212. https://doi.org/10.1186/1479-7364-4-3-207 (2010).
doi: 10.1186/1479-7364-4-3-207
pubmed: 20368142
pmcid: 3525972
Pettersen, E. F. et al. UCSF Chimera—A visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612. https://doi.org/10.1002/jcc.20084 (2004).
doi: 10.1002/jcc.20084
pubmed: 15264254
Tate, J. G. et al. COSMIC: The catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941–D947. https://doi.org/10.1093/nar/gky1015 (2018).
doi: 10.1093/nar/gky1015
pmcid: 6323903
Ng, P. C. & Henikoff, S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res. 31, 3812–3814. https://doi.org/10.1093/nar/gkg509 (2003).
doi: 10.1093/nar/gkg509
pubmed: 12824425
pmcid: 168916
Corsello, S. M. et al. Discovering the anticancer potential of non-oncology drugs by systematic viability profiling. Nat. Cancer 1, 235–248. https://doi.org/10.1038/s43018-019-0018-6 (2020).
doi: 10.1038/s43018-019-0018-6
pubmed: 32613204
pmcid: 7328899
Wishart, D. S. et al. DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Res. 46, D1074–D1082. https://doi.org/10.1093/nar/gkx1037 (2017).
doi: 10.1093/nar/gkx1037
pmcid: 5753335
Herbst, R. S. Review of epidermal growth factor receptor biology. Int. J. Radiat. Oncol. Biol. Phys. 59, S21–S26. https://doi.org/10.1016/j.ijrobp.2003.11.041 (2004).
doi: 10.1016/j.ijrobp.2003.11.041
Ferguson, K. M. Structure-based view of epidermal growth factor receptor regulation. Annu. Rev. Biophys. 37, 353–373. https://doi.org/10.1146/annurev.biophys.37.032807.125829 (2008).
doi: 10.1146/annurev.biophys.37.032807.125829
pubmed: 18573086
pmcid: 2745238
Rude Voldborg, B., Damstrup, L., Spang-Thomsen, M. & Skovgaard Poulsen, H. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann. Oncol. 8, 1197–1206. https://doi.org/10.1023/A:1008209720526 (1997).
doi: 10.1023/A:1008209720526
Radom, F., Vonrhein, C., Mittl, P. R. E. & Pluckthun, A. Crystal structures of HER3 extracellular domain 4 in complex with the designed ankyrin-repeat protein D5. Acta Crystallogr. F Struct. Biol. Commun. 77, 192–201. https://doi.org/10.1107/S2053230X21006002 (2021).
doi: 10.1107/S2053230X21006002
pubmed: 34196609
pmcid: 8248824
Ramalingam, S. S., Owonikoko, T. K. & Khuri, F. R. Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J. Clin. 61, 91–112. https://doi.org/10.3322/caac.20102 (2011).
doi: 10.3322/caac.20102
pubmed: 21303969
Oda, K., Matsuoka, Y., Funahashi, A. & Kitano, H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol. Syst. Biol. 1, 2005.0010. https://doi.org/10.1038/msb4100014 (2005).
doi: 10.1038/msb4100014
pubmed: 16729045
pmcid: 1681468
Steinway, S. N., Dang, H., You, H., Rountree, C. B. & Ding, W. The EGFR/ErbB3 pathway acts as a compensatory survival mechanism upon c-Met inhibition in human c-Met+ hepatocellular carcinoma. PLoS One 10, e0128159. https://doi.org/10.1371/journal.pone.0128159 (2015).
doi: 10.1371/journal.pone.0128159
pubmed: 26000702
pmcid: 4441360
Ueno, Y. et al. Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells. Int. J. Cancer 123, 340–347. https://doi.org/10.1002/ijc.23465 (2008).
doi: 10.1002/ijc.23465
pubmed: 18398842
Jena, B. et al. Specifically targeting the interface between HER1-HER3 heterodimer on breast cancer to limit off-target effects using chimeric antigen receptor designs with improved T-cell energy balance. Blood 124, 2151. https://doi.org/10.1182/blood.V124.21.2151.2151 (2014).
doi: 10.1182/blood.V124.21.2151.2151
Arena, S. et al. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Sci. Transl. Med. 8, 324ra314. https://doi.org/10.1126/scitranslmed.aad5640 (2016).
doi: 10.1126/scitranslmed.aad5640
Dokala, A. & Thakur, S. S. Extracellular region of epidermal growth factor receptor: A potential target for anti-EGFR drug discovery. Oncogene 36, 2337–2344. https://doi.org/10.1038/onc.2016.393 (2017).
doi: 10.1038/onc.2016.393
pubmed: 27775071
Croom, K. F. & Keam, S. J. Tipranavir. Drugs 65, 1669–1677. https://doi.org/10.2165/00003495-200565120-00005 (2005).
doi: 10.2165/00003495-200565120-00005
pubmed: 16060700
Schouten, J. T. FDA approves 2 new protease inhibitors: Ritonavir (Norvir) and Crixivan (Indinavir sulfate). Food and Drug Administration. STEP Perspect. 8, 7–8 (1996).
pubmed: 11363592
Brik, A. & Wong, C.-H. HIV-1 protease: Mechanism and drug discovery. Org. Biomol. Chem. 1, 5–14. https://doi.org/10.1039/B208248A (2003).
doi: 10.1039/B208248A
pubmed: 12929379
Sánchez-Martín, F. J. et al. The first-in-class anti-EGFR antibody mixture Sym004 overcomes cetuximab resistance mediated by EGFR extracellular domain mutations in colorectal cancer. Clin. Cancer Res. 22, 3260–3267. https://doi.org/10.1158/1078-0432.Ccr-15-2400 (2016).
doi: 10.1158/1078-0432.Ccr-15-2400
pubmed: 26888827
Scholar, E. In xPharm: The Comprehensive Pharmacology Reference (eds Enna, S. J. & Bylund, D. B.) 1–5 (Elsevier, 2007).
Lax, I. et al. Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling. Mol. Cell Biol. 8, 1831–1834. https://doi.org/10.1128/mcb.8.4.1831-1834.1988 (1988).
doi: 10.1128/mcb.8.4.1831-1834.1988
pubmed: 3260004
pmcid: 363348
Pietras, R. J. et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10, 2435–2446 (1995).
pubmed: 7784095
Tai, W., Mahato, R. & Cheng, K. The role of HER2 in cancer therapy and targeted drug delivery. J. Control. Release 146, 264–275. https://doi.org/10.1016/j.jconrel.2010.04.009 (2010).
doi: 10.1016/j.jconrel.2010.04.009
pubmed: 20385184
pmcid: 2918695
Engel, R. H. & Kaklamani, V. G. HER2-positive breast cancer. Drugs 67, 1329–1341. https://doi.org/10.2165/00003495-200767090-00006 (2007).
doi: 10.2165/00003495-200767090-00006
pubmed: 17547474
Emde, A., Kostler, W. J., Yarden, Y., Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME). Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer. Crit. Rev. Oncol. Hematol. 84(Suppl 1), e49–e57. https://doi.org/10.1016/j.critrevonc.2010.09.002 (2012).
doi: 10.1016/j.critrevonc.2010.09.002
pubmed: 20951604
Reichelt, U. et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod. Pathol. 20, 120–129. https://doi.org/10.1038/modpathol.3800712 (2007).
doi: 10.1038/modpathol.3800712
pubmed: 17143264
Fukushige, S. et al. Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol. Cell. Biol. 6, 955–958. https://doi.org/10.1128/mcb.6.3.955-958.1986 (1986).
doi: 10.1128/mcb.6.3.955-958.1986
pubmed: 2430175
pmcid: 367597
Iqbal, N. & Iqbal, N. Human epidermal growth factor receptor 2 (HER2) in cancers: Overexpression and therapeutic implications. Mol. Biol. Int. 2014, 852748. https://doi.org/10.1155/2014/852748 (2014).
doi: 10.1155/2014/852748
pubmed: 25276427
pmcid: 4170925
Meza-Junco, J., Au, H. J. & Sawyer, M. B. Trastuzumab for gastric cancer. Expert Opin. Biol. Ther. 9, 1543–1551. https://doi.org/10.1517/14712590903439702 (2009).
doi: 10.1517/14712590903439702
pubmed: 19916733
Nahta, R. & Esteva, F. J. HER2 therapy: Molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 8, 215. https://doi.org/10.1186/bcr1612 (2006).
doi: 10.1186/bcr1612
pubmed: 17096862
pmcid: 1797036
Johnston, S. R. & Leary, A. Lapatinib: A novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Drugs Today (Barc) 42, 441–453. https://doi.org/10.1358/dot.2006.42.7.985637 (2006).
doi: 10.1358/dot.2006.42.7.985637
pubmed: 16894399
Agus, D. B. et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2, 127–137. https://doi.org/10.1016/s1535-6108(02)00097-1 (2002).
doi: 10.1016/s1535-6108(02)00097-1
pubmed: 12204533
Subeha, M. R. & Telleria, C. M. The anti-cancer properties of the HIV protease inhibitor nelfinavir. Cancers https://doi.org/10.3390/cancers12113437 (2020).
doi: 10.3390/cancers12113437
pubmed: 33228205
pmcid: 7699465
Jensen, K. et al. Nelfinavir inhibits proliferation and induces DNA damage in thyroid cancer cells. Endocr. Relat. Cancer 24, 147–156. https://doi.org/10.1530/erc-16-0568 (2017).
doi: 10.1530/erc-16-0568
pubmed: 28137980
Monini, P. et al. Clinical course of classic Kaposi’s sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir. AIDS 23, 534–538. https://doi.org/10.1097/QAD.0b013e3283262a8d (2009).
doi: 10.1097/QAD.0b013e3283262a8d
pubmed: 19169139
Xiong, J. et al. The anti-HIV drug tipranavir induces gastric cancer stem cell apoptosis and exerts anticancer activity via the PRSS23–IL24 pathway (Research Square, 2022). https://doi.org/10.21203/rs.3.rs-1660593/v1 .
Rengan, R. et al. A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: A report of toxicities and clinical response. J. Thorac. Oncol. 7, 709–715. https://doi.org/10.1097/JTO.0b013e3182435aa6 (2012).
doi: 10.1097/JTO.0b013e3182435aa6
pubmed: 22425919
pmcid: 3310889
Rengan, R. et al. Clinical outcomes of the hiv protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: A phase 1/2 trial. JAMA Oncol. 5, 1464–1472. https://doi.org/10.1001/jamaoncol.2019.2095 (2019).
doi: 10.1001/jamaoncol.2019.2095
pubmed: 31436839
pmcid: 6707020
Brunner, T. B. et al. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J. Clin. Oncol. 26, 2699–2706. https://doi.org/10.1200/jco.2007.15.2355 (2008).
doi: 10.1200/jco.2007.15.2355
pubmed: 18509182
Baccarini, M. Second nature: Biological functions of the Raf-1 “kinase”. FEBS Lett. 579, 3271–3277. https://doi.org/10.1016/j.febslet.2005.03.024 (2005).
doi: 10.1016/j.febslet.2005.03.024
pubmed: 15943972
Weber, C. K., Slupsky, J. R., Kalmes, H. A. & Rapp, U. R. Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res. 61, 3595–3598 (2001).
pubmed: 11325826
Lavoie, H. & Therrien, M. Regulation of RAF protein kinases in ERK signalling. Nat. Rev. Mol. Cell Biol. 16, 281–298. https://doi.org/10.1038/nrm3979 (2015).
doi: 10.1038/nrm3979
pubmed: 25907612
Cope, N. et al. Mechanism of BRAF activation through biochemical characterization of the recombinant full-length protein. ChemBioChem 19, 1988–1997. https://doi.org/10.1002/cbic.201800359 (2018).
doi: 10.1002/cbic.201800359
pubmed: 29992710
pmcid: 6504641
Cook, F. A. & Cook, S. J. Inhibition of RAF dimers: It takes two to tango. Biochem. Soc. Trans. 49, 237–251. https://doi.org/10.1042/bst20200485 (2020).
doi: 10.1042/bst20200485
pmcid: 7924995
Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954. https://doi.org/10.1038/nature00766 (2002).
doi: 10.1038/nature00766
pubmed: 12068308
Holderfield, M., Deuker, M. M., McCormick, F. & McMahon, M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat. Rev. Cancer 14, 455–467. https://doi.org/10.1038/nrc3760 (2014).
doi: 10.1038/nrc3760
pubmed: 24957944
pmcid: 4250230
van der Burgt, I. Noonan syndrome. Orphanet J. Rare Dis. 2, 4. https://doi.org/10.1186/1750-1172-2-4 (2007).
doi: 10.1186/1750-1172-2-4
pubmed: 17222357
pmcid: 1781428
Wu, X. et al. Increased BRAF heterodimerization is the common pathogenic mechanism for noonan syndrome-associated RAF1 mutants. Mol. Cell. Biol. 32, 3872–3890. https://doi.org/10.1128/MCB.00751-12 (2012).
doi: 10.1128/MCB.00751-12
pubmed: 22826437
pmcid: 3457534
Aapro, M. S. Review of experience with ondansetron and granisetron. Ann. Oncol. 4, S9–S14. https://doi.org/10.1093/annonc/4.suppl_3.S9 (1993).
doi: 10.1093/annonc/4.suppl_3.S9
Liu, W. et al. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: Molecular mechanisms and clinical implications. J. Exp. Clin. Cancer Res. 39, 38. https://doi.org/10.1186/s13046-020-1539-7 (2020).
doi: 10.1186/s13046-020-1539-7
pubmed: 32085796
pmcid: 7035645
Durand, N. et al. Methiothepin increases chemotherapy efficacy against resistant melanoma cells. Molecules 26, 1867 (2021).
doi: 10.3390/molecules26071867
pubmed: 33810240
pmcid: 8037503
Razay, G. & Wilcock, G. K. Galantamine in Alzheimer’s disease. Expert Rev. Neurother. 8, 9–17. https://doi.org/10.1586/14737175.8.1.9 (2008).
doi: 10.1586/14737175.8.1.9
pubmed: 18088197
Ruiz-Espejo, F. et al. Breast cancer metastasis alters acetylcholinesterase activity and the composition of enzyme forms in axillary lymph nodes. Breast Cancer Res. Treat. 80, 105–114. https://doi.org/10.1023/A:1024461108704 (2003).
doi: 10.1023/A:1024461108704
pubmed: 12889604
Bernardi, C. C., Ribeiro Ede, S., Cavalli, I. J., Chautard-Freire-Maia, E. A. & Souza, R. L. Amplification and deletion of the ACHE and BCHE cholinesterase genes in sporadic breast cancer. Cancer Genet. Cytogenet. 197, 158–165. https://doi.org/10.1016/j.cancergencyto.2009.10.011 (2010).
doi: 10.1016/j.cancergencyto.2009.10.011
pubmed: 20193849
Ruiz-Espejo, F., Cabezas-Herrera, J., Illana, J., Campoy, F. J. & Vidal, C. J. Cholinesterase activity and acetylcholinesterase glycosylation are altered in human breast cancer. Breast Cancer Res. Treat. 72, 11–22. https://doi.org/10.1023/a:1014904701723 (2002).
doi: 10.1023/a:1014904701723
pubmed: 12000217
Saez-Valero, J., Poza-Cisneros, G. & Vidal, C. J. Molecular forms of acetyl- and butyrylcholinesterase in human glioma. Neurosci. Lett. 206, 173–176. https://doi.org/10.1016/s0304-3940(96)12452-6 (1996).
doi: 10.1016/s0304-3940(96)12452-6
pubmed: 8710179
Saez-Valero, J. & Vidal, C. J. Biochemical properties of acetyl- and butyrylcholinesterase in human meningioma. Biochim. Biophys. Acta 1317, 210–218. https://doi.org/10.1016/s0925-4439(96)00061-0 (1996).
doi: 10.1016/s0925-4439(96)00061-0
pubmed: 8988237
Zakut, H. et al. Acetylcholinesterase and butyrylcholinesterase genes coamplify in primary ovarian carcinomas. J. Clin. Investig. 86, 900–908. https://doi.org/10.1172/JCI114791 (1990).
doi: 10.1172/JCI114791
pubmed: 2394839
pmcid: 296809
Lazarević-Pašti, T., Leskovac, A., Momić, T., Petrovic, S. & Vasić, V. Modulators of acetylcholinesterase activity: From Alzheimer’s disease to anti-cancer drugs. Curr. Med. Chem. https://doi.org/10.2174/0929867324666170705123509 (2017).
doi: 10.2174/0929867324666170705123509
pubmed: 28685687
Andreeva, A., Howorth, D., Chothia, C., Kulesha, E. & Murzin, A. G. SCOP2 prototype: A new approach to protein structure mining. Nucleic Acids Res. 42, D310–D314. https://doi.org/10.1093/nar/gkt1242 (2013).
doi: 10.1093/nar/gkt1242
pubmed: 24293656
pmcid: 3964979
Andreeva, A., Kulesha, E., Gough, J. & Murzin, A. G. The SCOP database in 2020: Expanded classification of representative family and superfamily domains of known protein structures. Nucleic Acids Res. 48, D376–D382. https://doi.org/10.1093/nar/gkz1064 (2019).
doi: 10.1093/nar/gkz1064
pmcid: 7139981
Cox, A. D. & Der, C. J. The RAF inhibitor paradox revisited. Cancer Cell 21, 147–149. https://doi.org/10.1016/j.ccr.2012.01.017 (2012).
doi: 10.1016/j.ccr.2012.01.017
pubmed: 22340588
pmcid: 3285264
Dana, J. M. et al. SIFTS: Updated Structure Integration with Function, Taxonomy and Sequences resource allows 40-fold increase in coverage of structure-based annotations for proteins. Nucleic Acids Res. 47, D482–D489. https://doi.org/10.1093/nar/gky1114 (2018).
doi: 10.1093/nar/gky1114
pmcid: 6324003
Varadi, M. et al. PDBe and PDBe-KB: Providing high-quality, up-to-date and integrated resources of macromolecular structures to support basic and applied research and education. Protein Sci. 31, e4439. https://doi.org/10.1002/pro.4439 (2022).
doi: 10.1002/pro.4439
pubmed: 36173162
pmcid: 9517934
Jaiswal, B. S. et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell 23, 603–617. https://doi.org/10.1016/j.ccr.2013.04.012 (2013).
doi: 10.1016/j.ccr.2013.04.012
pubmed: 23680147
Kiavue, N. et al. ERBB3 mutations in cancer: Biological aspects, prevalence and therapeutics. Oncogene 39, 487–502. https://doi.org/10.1038/s41388-019-1001-5 (2020).
doi: 10.1038/s41388-019-1001-5
pubmed: 31519989
Arena, S. et al. Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin. Cancer Res. 21, 2157–2166. https://doi.org/10.1158/1078-0432.Ccr-14-2821 (2015).
doi: 10.1158/1078-0432.Ccr-14-2821
pubmed: 25623215
Newhall, K. et al. Frequency of S492R mutations in the epidermal growth factor receptor: Analysis of plasma Dna from metastatic colorectal cancer patients treated with panitumumab or cetuximab monotherapy. Ann. Oncol. 25, ii109. https://doi.org/10.1093/annonc/mdu193.11 (2014).
doi: 10.1093/annonc/mdu193.11
ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 578, 82–93. https://doi.org/10.1038/s41586-020-1969-6 (2020).
doi: 10.1038/s41586-020-1969-6
Bolton, K. L. et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat. Genet. 52, 1219–1226. https://doi.org/10.1038/s41588-020-00710-0 (2020).
doi: 10.1038/s41588-020-00710-0
pubmed: 33106634
pmcid: 7891089
Hyman, D. M. et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554, 189–194. https://doi.org/10.1038/nature25475 (2018).
doi: 10.1038/nature25475
pubmed: 29420467
pmcid: 5808581
Miao, D. et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat. Genet. 50, 1271–1281. https://doi.org/10.1038/s41588-018-0200-2 (2018).
doi: 10.1038/s41588-018-0200-2
pubmed: 30150660
pmcid: 6119118
Nguyen, B. et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell 185, 563-575.e511. https://doi.org/10.1016/j.cell.2022.01.003 (2022).
doi: 10.1016/j.cell.2022.01.003
pubmed: 35120664
pmcid: 9147702
Robinson, D. R. et al. Integrative clinical genomics of metastatic cancer. Nature 548, 297–303. https://doi.org/10.1038/nature23306 (2017).
doi: 10.1038/nature23306
pubmed: 28783718
pmcid: 5995337
Rosen, E. Y. et al. TRK fusions are enriched in cancers with uncommon histologies and the absence of canonical driver mutations. Clin. Cancer Res. 26, 1624–1632. https://doi.org/10.1158/1078-0432.Ccr-19-3165 (2020).
doi: 10.1158/1078-0432.Ccr-19-3165
pubmed: 31871300
Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51, 202–206. https://doi.org/10.1038/s41588-018-0312-8 (2019).
doi: 10.1038/s41588-018-0312-8
pubmed: 30643254
pmcid: 6365097
Wu, L. et al. Landscape of somatic alterations in large-scale solid tumors from an Asian population. Nat. Commun. 13, 4264. https://doi.org/10.1038/s41467-022-31780-9 (2022).
doi: 10.1038/s41467-022-31780-9
pubmed: 35871175
pmcid: 9308789
Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703–713. https://doi.org/10.1038/nm.4333 (2017).
doi: 10.1038/nm.4333
pubmed: 28481359
pmcid: 5461196
Cerami, E. et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404. https://doi.org/10.1158/2159-8290.Cd-12-0095 (2012).
doi: 10.1158/2159-8290.Cd-12-0095
pubmed: 22588877
Tong, L. et al. Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer. Theranostics 9, 5532–5541. https://doi.org/10.7150/thno.34070 (2019).
doi: 10.7150/thno.34070
pubmed: 31534501
pmcid: 6735385
Wan, P. T. et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855–867. https://doi.org/10.1016/s0092-8674(04)00215-6 (2004).
doi: 10.1016/s0092-8674(04)00215-6
pubmed: 15035987
Peng, S. B. et al. Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers. Cancer Cell 28, 384–398. https://doi.org/10.1016/j.ccell.2015.08.002 (2015).
doi: 10.1016/j.ccell.2015.08.002
pubmed: 26343583
Cocco, E., Lopez, S., Santin, A. D. & Scaltriti, M. Prevalence and role of HER2 mutations in cancer. Pharmacol. Ther. 199, 188–196. https://doi.org/10.1016/j.pharmthera.2019.03.010 (2019).
doi: 10.1016/j.pharmthera.2019.03.010
pubmed: 30951733
pmcid: 6571037
UniProt Consortium. UniProt: The universal protein knowledgebase in 2021. Nucleic Acids Res. 49, D480–D489. https://doi.org/10.1093/nar/gkaa1100 (2020).
doi: 10.1093/nar/gkaa1100
Halakou, F., Gursoy, A. & Keskin, O. In Protein-Protein Interaction Networks: Methods and Protocols (eds Canzar, S. & Ringeling, F. R.) 113–124 (Springer, US, 2020).
doi: 10.1007/978-1-4939-9873-9_9
Sterling, T. & Irwin, J. J. ZINC 15—Ligand discovery for everyone. J. Chem. Inf. Model. 55, 2324–2337. https://doi.org/10.1021/acs.jcim.5b00559 (2015).
doi: 10.1021/acs.jcim.5b00559
pubmed: 26479676
pmcid: 4658288
Fatma, C., Simge, S., Ahenk Zeynep, S., Attila, G. & Ozlem, K. DiPPI: A curated dataset for drug-like molecules in protein-protein interfaces. bioRxiv https://doi.org/10.1101/2023.08.09.552637 (2023).
doi: 10.1101/2023.08.09.552637
pubmed: 37808700
pmcid: 10557612
McPherson, A. & Gavira, J. A. Introduction to protein crystallization. Acta Crystallogr. F Struct. Biol. Commun. 70, 2–20. https://doi.org/10.1107/S2053230X13033141 (2014).
doi: 10.1107/S2053230X13033141
pubmed: 24419610
Vera, L., Czarny, B., Georgiadis, D., Dive, V. & Stura, E. A. Practical use of glycerol in protein crystallization. Crystal Growth Design 11, 2755–2762. https://doi.org/10.1021/cg101364m (2011).
doi: 10.1021/cg101364m
Laskowski, R. A., Jabłońska, J., Pravda, L., Vařeková, R. S. & Thornton, J. M. PDBsum: Structural summaries of PDB entries. Protein Sci. 27, 129–134. https://doi.org/10.1002/pro.3289 (2018).
doi: 10.1002/pro.3289
pubmed: 28875543
Gao, M. & Skolnick, J. iAlign: A method for the structural comparison of protein–protein interfaces. Bioinformatics 26, 2259–2265. https://doi.org/10.1093/bioinformatics/btq404 (2010).
doi: 10.1093/bioinformatics/btq404
pubmed: 20624782
pmcid: 2935406
Nguyen, T.-D., Schmidt, B. & Kwoh, C.-K. SparseHC: A memory-efficient online hierarchical clustering algorithm. Procedia Comput. Sci. 29, 8–19. https://doi.org/10.1016/j.procs.2014.05.001 (2014).
doi: 10.1016/j.procs.2014.05.001
Trott, O. & Olson, A. J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455–461. https://doi.org/10.1002/jcc.21334 (2010).
doi: 10.1002/jcc.21334
pubmed: 19499576
pmcid: 3041641
Cock, P. J. A. et al. Biopython: Freely available Python tools for computational molecular biology and bioinformatics. Bioinformatics 25, 1422–1423. https://doi.org/10.1093/bioinformatics/btp163 (2009).
doi: 10.1093/bioinformatics/btp163
pubmed: 19304878
pmcid: 2682512
Harris, C. R. et al. Array programming with NumPy. Nature 585, 357–362. https://doi.org/10.1038/s41586-020-2649-2 (2020).
doi: 10.1038/s41586-020-2649-2
pubmed: 32939066
pmcid: 7759461
O’Boyle, N. M. et al. Open Babel: An open chemical toolbox. J. Cheminform. 3, 33. https://doi.org/10.1186/1758-2946-3-33 (2011).
doi: 10.1186/1758-2946-3-33
pubmed: 21982300
pmcid: 3198950
Morris, G. M. et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 30, 2785–2791. https://doi.org/10.1002/jcc.21256 (2009).
doi: 10.1002/jcc.21256
pubmed: 19399780
pmcid: 2760638